Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease

  • Original Article
  • Published:
Sleep and Breathing Aims and scope Submit manuscript

Abstract

Purpose

Obstructive sleep apnea (OSA) is a common disorder with a high prevalence among patients with cardiovascular disease (CVD), diabetes, and chronic kidney disease (CKD). Routine evaluation of OSA for patients with CVD including hypertension has been performed according to the clinical guidelines for both OSA and CVD. However, most patients with diabetes and CKD who could benefit from treatment remain undiagnosed because routine screening of OSA is not recognized as part of standard practice. This study aims to evaluate the cost-effectiveness of OSA screening for patients with diabetes and CKD.

Methods

Cost-effectiveness analysis by a decision tree and Markov modeling from the societal perspective in Japan was carried out to provide evidence based on the economic evaluation of current clinical practice concerning diabetes and CKD.

Results

Incremental cost-effectiveness ratios of OSA screening compared with do-nothing were calculated as ¥3,516,976 to 4,514,813/quality-adjusted life year (QALY) (US$35,170 to 45,148/QALY) for diabetes patients and ¥3,666,946 to 4,006,866/QALY (US$36,669 to 40,069/QALY) for CKD patients.

Conclusions

Taking the threshold to judge cost-effectiveness according to a suggested value of social willingness to pay for one QALY gain in Japan as ¥5 million/QALY (US$50,000QALY), OSA screening is cost-effective. Our results suggest that active case screening and treatment of OSA for untreated middle-aged male patients with diabetes or CKD could be justifiable as an efficient use of finite health-care resources in the world with high prevalence of these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM (2013) Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177:1006–1014

    Article  PubMed Central  PubMed  Google Scholar 

  2. Jordan AS, McSharry DG, Malhotra A (2013) Adult obstructive sleep apnoea. Lancet 383:736–747

    Article  PubMed Central  PubMed  Google Scholar 

  3. Bazzano LA, Khan Z, Reynolds K, He J (2007) Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 50:417–423

    Article  CAS  PubMed  Google Scholar 

  4. Buchner NJ, Sanner BM, Borgel J, Rump LC (2007) Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 176:1274–1278

    Article  PubMed  Google Scholar 

  5. Young T, Skatrud J, Peppard PE (2004) Risk factors for obstructive sleep apnea in adults. JAMA 291:2013–2016

    Article  CAS  PubMed  Google Scholar 

  6. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP et al (2009) Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 5:263–276

    PubMed  Google Scholar 

  7. Harada Y, Oga T, Chin K, Takegami M, Takahashi K, Sumi K et al (2012) Differences in relationships among sleep apnoea, glucose level, sleep duration and sleepiness between persons with and without type 2 diabetes. J Sleep Res 21:410–418

    Article  PubMed  Google Scholar 

  8. Sakaguchi Y, Shoji T, Kawabata H, Niihata K, Suzuki A, Kaneko T et al (2011) High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 6:995–1000

    Article  PubMed Central  PubMed  Google Scholar 

  9. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ, International Diabetes Federation Taskforce on Epidemiology and Prevention (2008) Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 81:2–12

    Article  PubMed  Google Scholar 

  10. Turek NF, Ricardo AC, Lash JP (2012) Sleep disturbances as nontraditional risk factors for development and progression of CKD: review of the evidence. Am J Kidney Dis 60:823–833

    Article  PubMed Central  PubMed  Google Scholar 

  11. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR (2008) Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 31:1079–1085

    PubMed Central  PubMed  Google Scholar 

  12. Nakayama-Ashida Y, Takegami M, Chin K, Sumi K, Nakamura T, Takahashi K et al (2008) Sleep-disordered breathing in the usual lifestyle setting as detected with home monitoring in a population of working men in Japan. Sleep 31:419–425

    PubMed Central  PubMed  Google Scholar 

  13. Chin K, Nakamura T, Takahashi K, Sumi K, Matsumoto H, Niimi A et al (2006) Falls in blood pressure in patients with obstructive sleep apnoea after long-term nasal continuous positive airway pressure treatment. J Hypertens 24:2091–2099

    Article  CAS  PubMed  Google Scholar 

  14. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A et al (1997) Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 20:844–847

    Article  CAS  PubMed  Google Scholar 

  15. Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I et al (2010) Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol 14:333–339

    Article  PubMed  Google Scholar 

  16. Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T et al (2012) Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol 16:279–291

    Article  PubMed Central  PubMed  Google Scholar 

  17. Yokoyama H, Araki S, Haneda M, Matsushima M, Kawai K, Hirao K et al (2012) Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 55:1911–1918

    Article  CAS  PubMed  Google Scholar 

  18. Kimura Y, Takishita S, Muratani H, Kinjo K, Shinzato Y, Muratani A et al (1998) Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 37:736–745

    Article  CAS  PubMed  Google Scholar 

  19. Fukiyama K, Kimura Y, Wakugami K, Muratani H (2000) Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res 23:127–135

    Article  CAS  PubMed  Google Scholar 

  20. The Global Lower Extremity Amputation Study Group (2000) Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. Br J Surg 87:328–337

    Article  Google Scholar 

  21. Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA (2009) Mortality of first-time amputees in diabetics: a 10-year observation. Diabetes Res Clin Pract 83:126–131

    Article  PubMed  Google Scholar 

  22. Ministry of Health, Labour and Welfare (2013) Vital statistics of Japan 2011. Health and Welfare Statistics Association, Tokyo (in Japanese)

    Google Scholar 

  23. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford

    Google Scholar 

  24. Gold RM, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health care and medicine. Oxford University Press, New York

    Google Scholar 

  25. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H et al (2006) Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health 9:47–53

    Article  PubMed  Google Scholar 

  26. Tajima R, Kondo M, Kai H, Saito C, Okada M, Takahashi H et al (2010) Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol 14:340–348

    Article  PubMed  Google Scholar 

  27. Hisashige T (2000) Estimation of the quality of the life in patients with diabetes―economic estimation of healthcare service by disease management: report on Research on Health Services 2000. Ministry of Health, Labour and Welfare of Japan, Tokyo, pp 67-77 (in Japanese)

  28. Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi A, Saruta T (2008) Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 31:1373–1383

    Article  CAS  PubMed  Google Scholar 

  29. Jenkinson C, Stradling J, Petersen S (1997) Comparison of three measures of quality of life outcome in the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res 6:199–204

    Article  CAS  PubMed  Google Scholar 

  30. Hisashige T (2001). Estimation of the burden of disease in patients with diabetes: report on Research on Health Services 2001. Ministry of Health, Labour and Welfare of Japan, Tokyo, pp 91-98 (in Japanese)

  31. Japanese association of dialysis physicians (2012) J Jpn Assoc Dial Phys 27:91–108, in Japanese

    Google Scholar 

  32. Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M et al (2007) A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 46:157–162

    Article  PubMed  Google Scholar 

  33. Ikeda S, Kobayashi M (2010) Cost-effectiveness analysis metformin or pioglitazone combined with sulfonylurea in type 2 diabetes mellitus in Japan. J Jpn Diabet Soc 53:469–475 (in Japanese)

    Google Scholar 

  34. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsuytani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19:422–437

    Article  PubMed  Google Scholar 

  35. Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J et al (2013) GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66:140–150

    Article  PubMed  Google Scholar 

  36. Fleetham J, Ayas N, Bradley D, Fitzpatrick M, Oliver TK, Morrison D et al (2011) Canadian Thoracic Society 2011 guideline update: diagnosis and treatment of sleep disordered breathing. Can Respir J 18:25–47

    PubMed Central  PubMed  Google Scholar 

  37. Pietzsch JB, Garner A, Cipriano LE, Linehan JH (2011) An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea. Sleep 34:695–709

    PubMed Central  PubMed  Google Scholar 

  38. Weatherly HL, Griffin SC, Mc Daid C, Durée KH, Davies RJ, Stradling JR et al (2009) An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care 25:26–34

    Article  PubMed  Google Scholar 

  39. Sadatsafavi M, Marra CA, Ayas NT, Stradling J, Fleetham J (2009) Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea. Sleep Breath 13:241–252

    Article  PubMed  Google Scholar 

  40. Mar J, Rueda JR, Duran-Cantolla J, Schechterz C, Chilcott J (2003) The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J 21:515–522

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8577, Japan

    Reiko Okubo & Kunihiro Yamagata

  2. Department of Health Care Policy and Health Economics, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8577, Japan

    Masahide Kondo & Shu-ling Hoshi

Authors
  1. Reiko Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahide Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu-ling Hoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kunihiro Yamagata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahide Kondo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okubo, R., Kondo, M., Hoshi, Sl. et al. Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease. Sleep Breath 19, 1081–1092 (2015). https://doi.org/10.1007/s11325-015-1134-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11325-015-1134-x

Keywords

Search

Navigation